| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2023 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022 | TARRANT | USA | R44EY033626 | Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | 000 | 2 | NIH | 12/2/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $786,257 ) |
| | 2025 | 2025 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6402 | TARRANT | USA | U01EY035026 | Sonogenetic Restoration of Vision for Retinitis Pigmentosa | 000 | 2 | NIH | 4/28/2025 | $786,257 |
| | 2025 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022 | TARRANT | USA | R44EY031642 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 001 | 3 | NIH | 9/29/2025 | $0 |
| | 2025 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY031642 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 3 | NIH | 11/1/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $785,380 ) |
| | 2024 | 2024 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | U01EY035026 | Sonogenetic Restoration of Vision for Retinitis Pigmentosa | 000 | 1 | NIH | 4/19/2024 | $785,380 |
| | 2024 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY031642 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 3 | NIH | 3/15/2024 | $0 |
| | 2024 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 5 | NIH | 9/17/2024 | $0 |
| | 2024 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 000 | 5 | NIH | 5/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $875,350 ) |
| | 2023 | 2023 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY033626 | Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | 000 | 2 | NIH | 8/31/2023 | $875,350 |
|
| Issue Date FY: 2022 ( Subtotal = $2,486,779 ) |
| | 2022 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 000 | 5 | NIH | 8/5/2022 | $375,875 |
| | 2022 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 001 | 5 | NIH | 7/29/2022 | $737,805 |
| | 2022 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY031642 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 3 | NIH | 6/9/2022 | $656,220 |
| | 2022 | 2022 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY033626 | Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | 000 | 1 | NIH | 9/2/2022 | $716,879 |
| | 2022 | 2021 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 4 | NIH | 4/4/2022 | $0 |
| | 2022 | 2020 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL | BEDFORD | TX | 76022-6410 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 000 | 5 | NIH | 11/30/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,796,840 ) |
| | 2021 | 2021 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6410 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 000 | 4 | NIH | 6/17/2021 | $375,875 |
| | 2021 | 2021 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 002 | 4 | NIH | 9/9/2021 | $749,517 |
| | 2021 | 2021 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY031642 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 2 | NIH | 6/16/2021 | $678,626 |
| | 2021 | 2020 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 001 | 3 | NIH | 7/19/2021 | -$7,178 |
| | 2021 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 1312 BROWN TRL STE A | BEDFORD | TX | 76022-6410 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 3 | NIH | 3/31/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,629,166 ) |
| | 2020 | 2020 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R44EY031642 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 1 | NIH | 5/28/2020 | $779,869 |
| | 2020 | 2020 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 000 | 5 | NIH | 8/28/2020 | $384,200 |
| | 2020 | 2020 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 000 | 3 | NIH | 6/30/2020 | $387,500 |
| | 2020 | 2020 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 3 | NIH | 2/15/2020 | $77,597 |
|
| Issue Date FY: 2019 ( Subtotal = $2,113,283 ) |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 001 | 2 | NIH | 6/20/2019 | $106,020 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 000 | 4 | NIH | 6/20/2019 | $100,750 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 000 | 4 | NIH | 6/20/2019 | $384,200 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 001 | 3 | NIH | 9/2/2019 | $928,533 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 001 | 2 | NIH | 6/20/2019 | $387,500 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 001 | 3 | NIH | 9/2/2019 | $21,840 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 2 | NIH | 1/24/2019 | $109,200 |
| | 2019 | 2019 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 000 | 1 | NIH | 6/5/2019 | $75,240 |
|
| Issue Date FY: 2018 ( Subtotal = $1,624,382 ) |
| | 2018 | 2018 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY028216 | Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system | 000 | 1 | NIH | 9/4/2018 | $274,200 |
| | 2018 | 2018 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 001 | 3 | NIH | 9/13/2018 | $71,500 |
| | 2018 | 2018 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 000 | 3 | NIH | 7/12/2018 | $247,500 |
| | 2018 | 2018 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R44EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 2 | NIH | 9/20/2018 | $1,031,182 |
| | 2018 | 2016 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R43EY026483 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 1 | NIH | 7/11/2018 | $0 |
| | 2018 | 2015 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R43EY025905 | Ambient light activatable opsin based therapy for age-related macular degeneration | 000 | 1 | NIH | 2/27/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $247,500 ) |
| | 2017 | 2017 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R01EY025717 | Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment | 000 | 2 | NIH | 6/19/2017 | $247,500 |
| | 2017 | 2016 | NANOSCOPE TECHNOLOGIES LLC | 2519 RADCLIFFE DR | ARLINGTON | TX | 76012-5378 | TARRANT | USA | R43EY026483 | Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | 000 | 1 | NIH | 7/27/2017 | $0 |
|
|
